TCGA-46-3765-01A-01R-0980-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 59
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.610
- MYC_TARGETS_V2+0.560
- MTORC1_SIGNALING+0.520
- OXIDATIVE_PHOSPHORYLATION+0.480
- UNFOLDED_PROTEIN_RESPONSE+0.470
- CHOLESTEROL_HOMEOSTASIS+0.430
- PROTEIN_SECRETION+0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.370
- E2F_TARGETS+0.360
- DNA_REPAIR+0.340
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.310
- NOTCH_SIGNALING-0.310
- MITOTIC_SPINDLE-0.250
- MYOGENESIS-0.250
- TGF_BETA_SIGNALING-0.220
- APICAL_JUNCTION-0.210
- APICAL_SURFACE-0.180
- ESTROGEN_RESPONSE_EARLY-0.180
- ANGIOGENESIS-0.170
- BILE_ACID_METABOLISM-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 8824c0fd-764e-4525-952b-f25efa742772 | — | — | 0.885 |
| 2 | 17-020P2_Bladder | — | — | 0.873 |
| 3 | feccc57b-a987-4dd7-babf-1a8982bd64cc | — | — | 0.870 |
| 4 | SRR11296852 | — | — | 0.865 |
| 5 | bf312cd5-e251-4d63-95b5-c379b3ef5ded | — | — | 0.851 |
| 6 | be22f883.ee5e.4632.93d1.661ddc53608e | — | cohortA4 | 0.842 |
| 7 | TCGA-66-2727-01A-01R-0980-07 | — | cohortSQ2 | 0.839 |
| 8 | 77984740-019e-482f-822a-25a74ec2cc32 | — | — | 0.831 |
| 9 | TCGA-18-3411-01A-01R-0980-07 | — | cohortSQ2 | 0.831 |
| 10 | A07BA2E1-CCA0-4231-A391-B13383A2BCB9 | — | — | 0.829 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.610 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.560 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.520 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.480 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.470 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.430 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.370 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.340 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.250 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.210 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.180 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.150 | Inavolisib | — uncovered |